Staphylokinase is under clinical development by SupraGen and currently in Phase III for Ischemia. According to GlobalData, Phase III drugs for Ischemia have an 8% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Staphylokinase’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Staphylokinase overview

Staphylokinase (fortelyzin) is an enzyme secreted by several species of streptococci, which acts as fibrinolytic agent. It is formulated as solution for intravenous route of administration. It is indicated to treat acute myocardial infarction-segment elevation ST on ECG.

Staphylokinase is under development for the treatment of massive pulmonary embolism and acute limb ischemia. It is administered through intravenous route.

It was also under development for the treatment of coronavirus disease 2019 (covid-19).

For a complete picture of Staphylokinase’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.